Saroglitazar - Zydus Cadila

Drug Profile

Saroglitazar - Zydus Cadila

Alternative Names: Lipaglyn; Saroglitazar Magnesium; Saroglitazar Mg; ZY-H1

Latest Information Update: 17 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Zydus-Cadila
  • Developer Zydus Cadila; Zydus Discovery DMCC
  • Class Antihyperglycaemics; Antihyperlipidaemics; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Dyslipidaemias; Hypertriglyceridaemia
  • Phase III Lipodystrophy; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
  • Phase II Primary biliary cirrhosis

Most Recent Events

  • 23 Aug 2018 Phase-II clinical trials in Non-alcoholic fatty liver disease (In adults, In the elderly) in USA (PO) (NCT03639623)
  • 21 Aug 2018 Zydus Discovery DMCC plans a phase II trial for Non-alcoholic fatty liver disease in liver transplant patients (In adults, In the elderly) in USA (PO) (NCT03639623)
  • 06 Aug 2018 Zydus Discovery plans a phase II trial for Non-alcoholic fatty liver disease in September 2018 (NCT03617263)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top